0 Valutazioni

ID

12112

Descrizione

Evaluation Of The Impact Of A Call Center In Management Of Metastatic And/Or Advanced Renal Cell Carcinoma Patients Treated With Sunitinib (Sutent) In First Line; ODM derived from: https://clinicaltrials.gov/show/NCT02187042

collegamento

https://clinicaltrials.gov/show/NCT02187042

Keywords

  1. 24/09/15 24/09/15 - Julian Varghese
Caricato su

24 settembre 2015

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0

Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Commenti del gruppo di articoli per :

Commenti dell'articolo per :


    Non ci sono commenti

    Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

    Eligibility Metastatic/Advanced Renal Cell Carcinoma NCT02187042

    Eligibility Metastatic/Advanced Renal Cell Carcinoma NCT02187042

    Inclusion Criteria
    Descrizione

    Inclusion Criteria

    Alias
    UMLS CUI
    C1512693
    metastatic and/or advanced renal cell carcinoma patients treated with sunitinib in first line according to the summary of product characteristics
    Descrizione

    Renal Cell Carcinoma; Metastatic to | Renal Cell Carcinoma; Advanced phase | sunitinib

    Tipo di dati

    boolean

    Alias
    UMLS CUI [1,1]
    C0007134
    UMLS CUI [1,2]
    C0036525
    UMLS CUI [2,1]
    C0007134
    UMLS CUI [2,2]
    C0205179
    UMLS CUI [3]
    C1176020
    resolution of all adverse event (grade ≤ 1 according to the common terminology criteria for adverse events v 4.3 of june 2010) from a prior treatment by radiotherapy and/or surgery
    Descrizione

    Recovery of Function radiotherapy; surgery

    Tipo di dati

    boolean

    Alias
    UMLS CUI [1]
    C0599766
    patient who can be followed for 6 months
    Descrizione

    compliance

    Tipo di dati

    boolean

    Alias
    UMLS CUI [1]
    C1321605
    patient who has signed a consent form
    Descrizione

    consent; form

    Tipo di dati

    boolean

    Alias
    UMLS CUI [1,1]
    C0805443
    UMLS CUI [1,2]
    C0514044
    UMLS CUI [2,1]
    C0348078
    UMLS CUI [2,2]
    C0221198
    patient affiliated to a national health service
    Descrizione

    Organizational Affiliation patient affiliated to a national health service

    Tipo di dati

    boolean

    Alias
    UMLS CUI [1]
    C0029239
    sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception during the course of the study and for 28 days after the last dose of study treatment
    Descrizione

    Contraceptive methods | Childbearing Potential

    Tipo di dati

    boolean

    Alias
    UMLS CUI [1]
    C0700589
    UMLS CUI [2]
    C3831118
    Exclusion Criteria
    Descrizione

    Exclusion Criteria

    Alias
    UMLS CUI
    C0680251
    patient who is participating in another clinical study
    Descrizione

    participation in another clinical study

    Tipo di dati

    boolean

    Alias
    UMLS CUI [1]
    C2348568
    patient taken in charge by a home help service
    Descrizione

    Home help needed

    Tipo di dati

    boolean

    Alias
    UMLS CUI [1]
    C0578841
    patient with brain metastases not treated or symptomatic
    Descrizione

    brain metastases; symptomatic; not treated

    Tipo di dati

    boolean

    Alias
    UMLS CUI [1,1]
    C0220650
    UMLS CUI [1,2]
    C0332155
    UMLS CUI [2,1]
    C0220650
    UMLS CUI [2,2]
    C0231220
    patient with an eastern cooperative oncology group at inclusion > 2
    Descrizione

    eastern cooperative oncology group

    Tipo di dati

    boolean

    Alias
    UMLS CUI [1]
    C1512162
    patient with a rate of serum creatinine > 1.5 times the upper limit normal
    Descrizione

    serum creatinine > 1.5 mg/dl

    Tipo di dati

    boolean

    Alias
    UMLS CUI [1]
    C0201976
    patient with a rate of bilirubin > 2 mg/dl
    Descrizione

    bilirubin

    Tipo di dati

    boolean

    Alias
    UMLS CUI [1]
    C1557209
    patient with a rate of aspartate transaminase (asat) or alanine transaminase (alat) > 2.5 times the upper limit normal or > 5 times the upper limit normal for patients with hepatic metastases
    Descrizione

    aspartate transaminase; alanine transaminase;

    Tipo di dati

    boolean

    Alias
    UMLS CUI [1]
    C0201899
    UMLS CUI [2]
    C0201836

    Similar models

    Eligibility Metastatic/Advanced Renal Cell Carcinoma NCT02187042

    Name
    genere
    Description | Question | Decode (Coded Value)
    Tipo di dati
    Alias
    Item Group
    C1512693 (UMLS CUI)
    Renal Cell Carcinoma; Metastatic to | Renal Cell Carcinoma; Advanced phase | sunitinib
    Item
    metastatic and/or advanced renal cell carcinoma patients treated with sunitinib in first line according to the summary of product characteristics
    boolean
    C0007134 (UMLS CUI [1,1])
    C0036525 (UMLS CUI [1,2])
    C0007134 (UMLS CUI [2,1])
    C0205179 (UMLS CUI [2,2])
    C1176020 (UMLS CUI [3])
    Recovery of Function radiotherapy; surgery
    Item
    resolution of all adverse event (grade ≤ 1 according to the common terminology criteria for adverse events v 4.3 of june 2010) from a prior treatment by radiotherapy and/or surgery
    boolean
    C0599766 (UMLS CUI [1])
    compliance
    Item
    patient who can be followed for 6 months
    boolean
    C1321605 (UMLS CUI [1])
    consent; form
    Item
    patient who has signed a consent form
    boolean
    C0805443 (UMLS CUI [1,1])
    C0514044 (UMLS CUI [1,2])
    C0348078 (UMLS CUI [2,1])
    C0221198 (UMLS CUI [2,2])
    Organizational Affiliation patient affiliated to a national health service
    Item
    patient affiliated to a national health service
    boolean
    C0029239 (UMLS CUI [1])
    Contraceptive methods | Childbearing Potential
    Item
    sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception during the course of the study and for 28 days after the last dose of study treatment
    boolean
    C0700589 (UMLS CUI [1])
    C3831118 (UMLS CUI [2])
    Item Group
    C0680251 (UMLS CUI)
    participation in another clinical study
    Item
    patient who is participating in another clinical study
    boolean
    C2348568 (UMLS CUI [1])
    Home help needed
    Item
    patient taken in charge by a home help service
    boolean
    C0578841 (UMLS CUI [1])
    brain metastases; symptomatic; not treated
    Item
    patient with brain metastases not treated or symptomatic
    boolean
    C0220650 (UMLS CUI [1,1])
    C0332155 (UMLS CUI [1,2])
    C0220650 (UMLS CUI [2,1])
    C0231220 (UMLS CUI [2,2])
    eastern cooperative oncology group
    Item
    patient with an eastern cooperative oncology group at inclusion > 2
    boolean
    C1512162 (UMLS CUI [1])
    serum creatinine > 1.5 mg/dl
    Item
    patient with a rate of serum creatinine > 1.5 times the upper limit normal
    boolean
    C0201976 (UMLS CUI [1])
    bilirubin
    Item
    patient with a rate of bilirubin > 2 mg/dl
    boolean
    C1557209 (UMLS CUI [1])
    aspartate transaminase; alanine transaminase;
    Item
    patient with a rate of aspartate transaminase (asat) or alanine transaminase (alat) > 2.5 times the upper limit normal or > 5 times the upper limit normal for patients with hepatic metastases
    boolean
    C0201899 (UMLS CUI [1])
    C0201836 (UMLS CUI [2])

    Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

    I campi contrassegnati da * sono obbligatori.

    Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

    Watch Tutorial